freephone 0800 862 0373
Sign in to view your quotes
Email address:
Password or PIN:

Forgotten your password? Reset it here.

NICE considering abiraterone for the NHS after discounted price

Published on 16/05/2012

The National Institute for Health and Clinical Excellence (NICE) has reversed its decision on prostate cancer drug abiraterone after the manufacturer offered the treatment at a lower price.

Abiraterone costs around £3,000 a month and was initially rejected in February 2012 by NICE for not being cost effective. The decision prompted anger from patients and cancer charities.

The outlook for prostate cancer is generally good, because it usually progresses very slowly. However, if the cancer spreads from the prostate to other parts of the body, it cannot be cured, and treatment is focused on prolonging life and relieving symptoms.

Currently, there are only two drugs licensed in Britain that are proven to given advanced prostate cancer patients more time: cabazitaxel and abiraterone. Just last week, prostate cancer drug cabazitaxel was turned down for use on the NHS by the National Institute of Health and Clinical Excellence (NICE).

During a consultation on abiraterone, the manufacturer of the drug, submitted further information for the committee to consider.

The drug will be provided to the NHS at a discounted price. The scale of the discount has not been made public.

Owen Sharp, the head of The Prostate Cancer Charity, said: "This announcement represents a resounding triumph for each of the thousands of men with advanced prostate cancer in England and Wales who know just how much the prospect of precious extra time with their loved ones really means.”

If NICE approves the drug in June, it will have to be offered by the NHS in England and Wales. At the moment, patients in England can access the drug through the Cancer Drugs Fund or through health insurance.

A decision will be made in Northern Ireland after the final recommendation is made by NICE. The Scottish Medicines Consortium has already turned down abiraterone for use on the NHS in Scotland, but is still in discussion with the manufacturers.

If you want to guarantee access to licensed cancer treatment, whether or not it is approved by NICE, compare private medical insurance policies with full cancer cover.

© ActiveQuote Ltd. 2012


Categories:  Medical
NICE considering abiraterone for the NHS after discounted priceThe National Institute for Health and Clinical Excellence (NICE) has reversed its decision on prostate cancer drug abiraterone after the man    tweet it on twittershare with your friends on Facebookshare with your friends on MySpaceBlog it on your LinkedIn profile
 

No.1 health insurance broker as rated by customers

Good value and the advisor was very helpful and recommended the best policy for my grandson. I would definitely use this service again and recommend to others.

Review centre member

We were contacted in good time to make a knowledgable choice. We were given plenty of options with lots of information to enable us to make the right choice.

Review centre member

The service I received was excellent, the staff member was very efficient and knowledgable. She went out of her way to get the best policy for me.

Review centre member

Great service. I really appreciated the help provided by Active Quote to arrange health insurance. The agent was very informative and proactive. Many thanks!

Review centre member

I received excellent care and attention from the first phone call till the last. Friendly, efficient and patient.

Review centre member

Staff are very helpful, friendly and polite. They call back when they say they will and keep you up to date with progress. Pleasure to deal with.

Review centre member

Very polite and friendly, and gave detailed explanations of all aspects of the cover. Reassuring to know that if you do have a problem there is someone you can contact.

Review centre member

Friendly and efficient. Nothing was too much trouble even when i needed to make a small change, excellent service.

Review centre member

The advisor was incredibly helpful and fully explained the differences between the policies. I really liked the fact that I was put under no pressure.

Review centre member

I was pleasantly surprised with the in-depth knowledge, the efficiency and the nice and polite manner of the staff - the explanations were made very clearly.

Review centre member
 
This site is operated by Insurance Broker ActiveQuote Ltd registered in England & Wales company number 6765845.
Authorised and Regulated by the Financial Conduct Authority (FCA). Firm reference number 501109 as detailed on the Financial Services Register. Please read our Key Facts document.
For information about your rights as a consumer visit Citizens Advice.

Our insurance comparison service is free and easy for you to use, but you are responsible for making sure all your information is entered correctly, and for choosing your insurer.

This site uses cookies in order to work correctly - these are not harmful and do not contain personal information. By using this site you consent to this. I understand  Tell me more

please wait ...